It's increasingly difficult to generate a big move in shares of a big biotech, but Alzheimer's disease (AD) did the trick again for Biogen Idec Inc., which continued to report upbeat findings for aducanumab (BIIB037) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France.